Staged Management of Obstructing Distal Transverse Colon Cancer with Suspected Peritoneal Metastasis

Diagnostic Staging

Diagnostic laparoscopy provides 85 % sensitivity and 100 % specificity for detecting peritoneal metastases that are not visible on CT, making it the preferred staging tool when peritoneal disease is suspected. 3
Contrast‑enhanced CT has a 3.9 % false‑positive rate but a substantial false‑negative rate for peritoneal disease, underscoring the need for laparoscopy when imaging is equivocal. 4
Confirmation of peritoneal metastases shifts treatment intent from curative to palliative and mandates systemic chemotherapy as the primary modality. 5

In patients with left‑sided or distal transverse colon obstruction and suspected metastatic disease, a diverting loop ileostomy without primary tumor resection is recommended to relieve obstruction while allowing rapid initiation of systemic therapy. [1][7]
This approach avoids prophylactic resection of an asymptomatic primary tumor, a practice that remains controversial and is being evaluated in prospective trials. 7
By minimizing operative trauma, the diverting ileostomy enables chemotherapy to start without the 6–8‑week delay required for recovery after major resection. 7
The strategy preserves the option of definitive resection later if the tumor responds well to chemotherapy. 7

Self‑expanding metal stents (SEMS) are not recommended as a standard bridge‑to‑surgery for obstructing left‑sided colon cancer; they may be used only in highly selected centers and are contraindicated when bevacizumab‑based therapy is planned because of a high perforation risk. [1][8]
Emergency resection with primary anastomosis carries approximately three‑fold higher morbidity and mortality compared with elective surgery and would delay systemic therapy by 6–8 weeks, making it unsuitable for malnourished patients with suspected metastases. [8][7]

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered only in highly selected patients who meet all of the following:
- Peritoneal Cancer Index (PCI) < 20
- Limited small‑bowel involvement
- No extra‑abdominal metastases
- Good performance status
- Feasibility of complete cytoreduction
- Treatment must be performed in a specialized center. 5
Patients with poor nutritional status and urgent need for decompression do not meet these criteria and are therefore poor immediate candidates for CRS/HIPEC. 5

Comprehensive molecular profiling (RAS, BRAF, MSI/MMR) is mandatory on peritoneal biopsy specimens, with a turnaround time ≤ 10 days to avoid delaying therapy. 6
For patients requiring rapid disease control (ESMO Group 2), the most active combination chemotherapy (FOLFOX or FOLFIRI) should be used as first‑line treatment. 9
Anti‑EGFR antibodies (cetuximab or panitumumab) are added when the tumor is RAS wild‑type and left‑sided. 6
Bevacizumab is added when the tumor harbors a RAS mutation or when anti‑EGFR therapy is contraindicated. 9

Aggressive nutritional support should be provided throughout chemotherapy to correct hypoalbuminemia; a feeding tube is considered when oral intake is insufficient. 10

Imaging and clinical reassessment at 2–3 months of systemic therapy:
- Excellent response → consider definitive resection of the primary tumor.
- Stable or responding disease → continue chemotherapy; defer resection unless symptoms develop.
- Progressive disease → shift focus to palliative care and maintain the diverting ostomy. 7

Perform complete staging CT (chest/abdomen/pelvis) with IV contrast to confirm absence of distant metastases. 4
Neoadjuvant chemotherapy (e.g., 3 months of FOLFOX or CAPOX) is supported by the FOxTROT trial, which demonstrated significant histopathologic down‑staging and improved 2‑year disease control. [4][7]
After neoadjuvant therapy, proceed with definitive surgery (extended right hemicolectomy or transverse colectomy with en‑bloc lymphadenectomy) once nutritional status has improved. 2
Primary anastomosis is performed after nutritional optimization, with ileostomy reversal at the same operation if feasible. [2][1]
Complete 6 months of peri‑operative chemotherapy (pre‑operative plus post‑operative) to maximize disease control. [2][7]

During active chemotherapy:
- Clinical assessment every 2 weeks. 9
- CT chest/abdomen/pelvis every 2–3 months to monitor response. 6
- Serum CEA measurement every 3 months if elevated at baseline. 11
After treatment completion (if disease controlled):
- Clinical visits every 3 months for the first 3 years, then every 6 months in years 4–5. 5
- CT chest/abdomen/pelvis every 6 months for 3 years in high‑risk patients. 5
- Colonoscopy at 1 year post‑treatment, then every 3–5 years if no polyps are found. [5][11]
- Serum CEA every 3–6 months for patients eligible for aggressive salvage therapy. 11

All facts are derived from peer‑reviewed guidelines and studies; strength of evidence was not explicitly graded in the source material.